The FDA approved a new indication for ACAM2000, to include the prevention of mpox disease in individuals determined to be at high risk for mpox infection. ACAM2000 has been approved since 2007 for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection. ACAM2000 is a live replicating vaccinia virus vaccine.
Quick Links: HOME | ABOUT | MEMBERSHIP | EDUCATION | CALENDAR | RESOURCES | CREDENTIALS
Also from ABSA International: Applied Biosafety: Journal of ABSA International | ABSA Job Board | BiosafetyBuyersGuide.org | Annual Biosafety and Biosecurity Conference | International Biosecurity Symposium | USDA ARS International Biosafety & Biocontainment Symposium | Biosafety & Biosecurity Training Course (BBTC®) | Principles & Practices of Biosafety® | my.ABSA.org | Risk Group Database | LAI Database | connect.ABSA.org
ABSA International
1200 Allanson Road, Mundelein, IL 60060-3808
1-866-425-1385 (toll free) or 847-949-1517
info@absa.org | Contact ABSA
Copyright © ABSA International. All Rights Reserved. Privacy Policy
ABSA International does not endorse, promote, review, or warrant the accuracy of the products and services offered by those parties who link to the ABSA International website. The links are merely provided as a convenience to the visitors of this site, and ABSA International may or may not be compensated for permitting the link to be displayed on this page.
